Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD (COPD1722)

University Hospital, Lille

Status: Enrolling

Conditions: Pulmonary Disease, Chronic Obstructive; Bacterial Infections

Treatments: Other: Sample collecting; Other: Lung function measure

Study type: Interventional

Funder types: Other

Identifiers

NCT02655302

2013_76

2015-A00190-49 (Other Identifier)

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD) is a worldwide chronic inflammatory disease of the airways linked to environmental exposure. The chronic course of COPD is often interrupted by acute exacerbations which have a major impact on the morbidity and mortality of COPD patients. A bacterial etiology for these exacerbations is common (almost 50%). Moreover, airway bacterial colonization linked to an increased susceptibility is observed in COPD patients. Effective Th17 immune response is needed to develop a good response against bacteria. Thus, this study aims to demonstrate that there is a defective IL-17/ IL-22 response to bacteria in COPD leading to airway bacterial colonization and infection.

Enrollment: 100 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed COPD according GOLD guidelines
• Current or ex-smoker (at least 10 pack-years)
• Hospitalized for COPD exacerbation

Exclusion criteria

• Asthma or Cystic fibrosis
• No other chronic lung disease
• Solid Tumor unhealed or not considered in remission
• Inhaled drug consumption
• Women of childbearing potential without effective contraception
• Pregnant or breastfeeding women
• Incapable of consent
• Lack of social security coverage

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Bacterial exacerbations

Other group

Description:

Patients with at least 10^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.

Treatment:

Other: Lung function measure

Other: Sample collecting

Non-bacterial exacerbations

Other group

Description:

Patients without detected bacteria or below 10^7 UFC/ml in sputum during their first COPD exacerbation.

Treatment:

Other: Lung function measure

Other: Sample collecting